НЕЙРОГУМОРАЛЬНЫЙ ДИСБАЛАНС КАК ПРИЧИНА ДИСФУНКЦИИ ПОЧКИ ПРИ ПЕРВИЧНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ
https://doi.org/10.24884/1561-6274-2004-8-1-29-35
Аннотация
Об авторах
О. Б. КузьминРоссия
Кафедры фармакологии и госпитальной терапии
М. О. Пугаева
Россия
Кафедры фармакологии и госпитальной терапии
Список литературы
1. Лебедев АА, Бранчевский ЛЛ, Карышева СС, Кузь мин ОБ. Натрийурез, объем циркулирующей крови при гемодинамических сдвигах, вызванных изменением сосудистого тонуса. Кардиология 1972; 12 (2): 99106
2. Guyton AC, Coleman TG, Cowley AW et al. Arterial pressure regulation. Overreading dominance of the kidneys in longterm regulation and in hypertension. Am J Med 1972; 52 (5): 584594
3. Кузьмин ОБ. Дисфункция почек при сердечной недостаточности и ее лекарственная коррекция. Медицина: М.; 2003: 152
4. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11(2): 197 200
5. Ciriello J, de Oliveira CV. Renal afferents and hypertension. Curr Hypertens Rep 2002; 4 (2): 136142
6. Шустов СБ, Баранов ВЛ, Яковлев ВА, Карлов ВА. Артериальные гипертензии. Специальная литература: СПб; 1997: 320
7. Shirley DG, Unwin RJ. Adrenal steroids and the kidney: 11Іhydroxysteroid dehydrogenase and renal function. J Physiol Proc 2000; 523: 3435
8. Elijovich F, Loffer CL, Amador E et al. Regulation of plasma endothelin in saltsensitive hypertension. Circulation 2001; 103 (2): 263268
9. Iglarz M, Schiffrin EL. Role of endothelin1 in hypertension. Curr Hypertens Rep 2003; 5 (2):144148
10. Melander O, Fradsen E, Groop L, Hulthen VL. Plasma proANP reflects saltsensitivity in subjects with heredity for hypertension. Hypertension 2002; 39 (5): 996999
11. Некрасова АА, Клембовский АА, Левицкая ЮВ и др. Простагландины почек и гипертоническая болезнь. Там же 1986; 16 (3): 1321
12. Ishimitsu T, Nishikimi T, Saito Y. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1999; 94 (5): 21582161
13. Kato J, Kitamura K, Matsui E et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999; 22 (1): 6165
14. Granger JP, Alexander BT, Llinas M. Mechanisms of pressure natriuresis. Curr Hypertens Rep 2002; 4 (2):152159
15. Guyton AC, Coleman TG, Cowley AW et al. Arterial pressure regulatuon. In: Laragh JH, ed. Hypertension. New York, 1975; 124
16. Weinberger MH, Miller JZ, Senftlerber I et al. Definitions and characteristics of salt sensitivity and blood pressure resistance. Hypertension 1986; 8 (Pt. 2): P.II127 II134
17. Wienberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27 (3): 481490
18. Su YR, Menon AJ. Epithelial sodium channels and hypertension. Drug Metabol Dispos 2001; 25 (4): 553556
19. Abassi ZA, Ellahham S, Winaver J, Hoffman A. The intrarenal endothelin system and hypertension. News Physiol Sci 2001; 16 (4):152156
20. Strazzullo P, Galletti F, Barba J. Altered renal handling of sodium in human hypertension. Hypertension 2003; 41 (5): 10001005
21. Johnston RJ, RodrignezIturbe B, Schreiner GF, Herrera Acasba J. Hypertension: a microvascular and tubulointerstitial disease. J Hypertens 2002; [Suppl 3]: S1S7
22. Simons JL, Provoost AP, Anderson S et al. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 1994; 46 (3): 396404
23. Semplicini A, Ceolotto G, Sartori M et al. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide. J Nephrol 2002; 15, (5): 489496
24. Boffa JJ. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14 (5):11321144
25. Edigo J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49 (3): 578597
26. Redon J. Renal protection with antihypertensive drugs: insights from microalbuminuria studies. J Hypertens 1998; 16: 20912100
27. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Ttial (FASET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (4): 597603
28. Brown NJ, Vanghan DE, Fogo AV. Aldosterone and PAI 1: implications for renal injury. J Nephrol 2002; 15(3): 230235
29. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37 (4): 677688
30. Blasi ER, Rocha R, Rudolph AE et al. Аldosterone/salt induced renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63 (5): 17911798
31. Комаров АП. Новости доказательной медицины. Сердце 2002; 1 (5): 257258
32. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37(2): 490496
33. Gomezgarre D, Ruizortega M, Ortego M et al. Effects and interactions of endothelin1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996; 27 (5): 885992
34. Rothermund L, Traupe T, Dieterich M et al. Nephroprotective effects of endothelin ET(A) receptor antagonist darusentan in saltsensitive genetic hypertension. Eur J Pharmacol 2003; 68 (3): 209216
35. Trenkner J, Priem F, Bauer C et al. Endothelin receptor A blockade reduced proteinuria and vascular hypertrophy in spontaneously hypertensive rats on highsalt diet in a blood pressureindependent manner. Clin Sci 2002; 103 [Suppl 48]: 385S388S
Рецензия
Для цитирования:
Кузьмин О.Б., Пугаева М.О. НЕЙРОГУМОРАЛЬНЫЙ ДИСБАЛАНС КАК ПРИЧИНА ДИСФУНКЦИИ ПОЧКИ ПРИ ПЕРВИЧНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ. Нефрология. 2004;8(1):29-35. https://doi.org/10.24884/1561-6274-2004-8-1-29-35
For citation:
Kuzmin O.B., Pugaeva M.O. NEUROHUMORAL DYSBALANCE AS A CAUSE OF RENAL DYSFUNCTION IN PRIMARY ARTERIAL HYPERTENSION. Nephrology (Saint-Petersburg). 2004;8(1):29-35. (In Russ.) https://doi.org/10.24884/1561-6274-2004-8-1-29-35